Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:ELUT NASDAQ:MIRA NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.62-4.3%$3.91$2.66▼$7.00$42.83M0.3429,221 shs13,899 shsELUTElutia$1.05$1.10$0.50▼$2.64$44.92M0.75125,957 shs48,204 shsMIRAMIRA Pharmaceuticals$0.97-4.8%$1.08$0.90▼$2.45$42.86M1.48141,362 shs160,213 shsRVPHReviva Pharmaceuticals$0.35-55.7%$1.36$0.26▼$23.20$10.19M0.75367,588 shs13.05 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-4.35%+2.21%+26.23%+33.18%+11.33%ELUTElutia0.00%+2.94%-4.55%+10.38%-44.74%MIRAMIRA Pharmaceuticals-4.80%-2.90%-5.73%-17.71%-17.71%RVPHReviva Pharmaceuticals-55.73%-60.00%-59.48%-93.13%-97.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.62-4.3%$3.91$2.66▼$7.00$42.83M0.3429,221 shs13,899 shsELUTElutia$1.05$1.10$0.50▼$2.64$44.92M0.75125,957 shs48,204 shsMIRAMIRA Pharmaceuticals$0.97-4.8%$1.08$0.90▼$2.45$42.86M1.48141,362 shs160,213 shsRVPHReviva Pharmaceuticals$0.35-55.7%$1.36$0.26▼$23.20$10.19M0.75367,588 shs13.05 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-4.35%+2.21%+26.23%+33.18%+11.33%ELUTElutia0.00%+2.94%-4.55%+10.38%-44.74%MIRAMIRA Pharmaceuticals-4.80%-2.90%-5.73%-17.71%-17.71%RVPHReviva Pharmaceuticals-55.73%-60.00%-59.48%-93.13%-97.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.00HoldN/AN/AELUTElutia 2.50Moderate Buy$6.00471.43% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ARVPHReviva Pharmaceuticals 2.50Moderate Buy$66.6718,834.01% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, ELUT, MIRA, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026RVPHReviva Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/8/2026RVPHReviva Pharmaceuticals Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/27/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/5/2026RVPHReviva Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AELUTElutia$12.29M3.65N/AN/A$0.65 per share1.62MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$1.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/AN/AELUTElutia$53.38M$0.821.28N/AN/A282.63%N/A-49.57%5/14/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.53N/AN/AN/AN/A-210.90%-198.94%6/3/2026 (Estimated)RVPHReviva Pharmaceuticals-$19.86M-$9.20N/AN/AN/AN/A-959.78%-162.27%5/21/2026 (Estimated)Latest RVPH, ELUT, MIRA, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026RVPHReviva Pharmaceuticals-$0.3333N/AN/AN/AN/AN/A5/14/2026Q1 2026ELUTElutia-$0.15N/AN/AN/A$3.00 millionN/A5/13/2026Q1 2026RVPHReviva Pharmaceuticals-$0.75-$0.46+$0.29-$0.46N/AN/A3/11/2026Q4 2025ELUTElutia-$0.14-$0.14N/A$1.48$3.30 million$3.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A21.97N/AELUTElutiaN/A2.222.12MIRAMIRA PharmaceuticalsN/A15.7515.75RVPHReviva PharmaceuticalsN/A2.082.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%ELUTElutia74.03%MIRAMIRA Pharmaceuticals35.16%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%ELUTElutia27.60%MIRAMIRA Pharmaceuticals6.65%RVPHReviva Pharmaceuticals8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableELUTElutia18042.79 million30.98 millionNot OptionableMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableRVPHReviva Pharmaceuticals512.81 million11.67 millionOptionableRVPH, ELUT, MIRA, and ATHE HeadlinesRecent News About These CompaniesReviva Pharmaceuticals (RVPH) Projected to Post Quarterly Earnings on ThursdayMay 14 at 2:09 AM | americanbankingnews.comReviva Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13 at 4:35 PM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)April 21, 2026 | theglobeandmail.comMaxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress PlansApril 20, 2026 | insidermonkey.comReviva Pharmaceuticals: Reviva Announces Letter to ShareholdersApril 15, 2026 | finanznachrichten.deReviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine DevelopmentApril 15, 2026 | quiverquant.comQReviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00April 9, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy†from AnalystsApril 6, 2026 | defenseworld.netDRVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2April 1, 2026 | msn.comReviva Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 30, 2026 | globenewswire.comReviva Pharmaceuticals Announces One-for-Twenty Reverse Stock SplitMarch 26, 2026 | theglobeandmail.comAnalysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitMarch 25, 2026 | insidermonkey.comTop 10 Stocks Under $5 That Could TripleMarch 24, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingMarch 23, 2026 | finance.yahoo.comReviva Pharmaceuticals Announces $10 Million Equity OfferingMarch 19, 2026 | tipranks.comWhat's Behind The Drop In Reviva Pharmaceuticals Stock?March 19, 2026 | benzinga.comWhy did RVPH stock crash 40% in pre-market today?March 19, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering of Common Stock and WarrantsMarch 18, 2026 | quiverquant.comQReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingMarch 18, 2026 | globenewswire.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingMarch 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026RVPH, ELUT, MIRA, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.62 -0.21 (-4.35%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$4.66 +0.04 (+0.87%) As of 05/13/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Elutia NASDAQ:ELUT$1.05 0.00 (0.00%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.08 +0.03 (+2.67%) As of 07:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.MIRA Pharmaceuticals NASDAQ:MIRA$0.97 -0.05 (-4.80%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$0.99 +0.02 (+2.37%) As of 07:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Reviva Pharmaceuticals NASDAQ:RVPH$0.35 -0.44 (-55.73%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$0.35 0.00 (-0.60%) As of 05/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
